One of the world's first successful semi-automatic handguns, the C96 "Broomhandle" Mauser pistol is often associated with ...

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, ...

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell ...

Unlike other Rossi lever-actions chambered for pistol cartridges, the Rossi R95 is chambered for the all-American .30-30 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.

The latest price target for Artiva Biotherapeutics (NASDAQ:ARTV) was reported by Needham on May 15, 2025. The analyst firm set a price target for $18.00 expecting ARTV to rise to within 12 months ...